XML 32 R18.htm IDEA: XBRL DOCUMENT

Warrants	9 Months Ended
Jan. 31, 2023
Warrants
Warrants	(11) Warrants Equity Classified Warrants On April 8, 2019, the Company issued and sold 1,542,000 shares of common stock, and pre-funded warrants to purchase up to 3,385,680 shares of common stock. The public offering price for the pre-funded warrants was equal to the public offering price of the common stock, less the $0.01 per share exercise price of each warrant. The pre-funded warrants have no expiration date. As of January 31, 2023, all of the pre-funded warrants had been exercised. The underwritten public offering also included the issuance of common stock warrants to purchase up to 4,927,680 shares of common stock that have an exercise price of $3.85 per share and expire five years from the issuance date. As of January 31, 2023, common warrants to purchase 732,500 shares of the common stock had been exercised. The pre-funded and common warrants issued in the Company’s April 8, 2019 public offering did not meet the criteria to be classified as a liability award and therefore were treated as an equity award and recorded as a component of shareholders’ equity in the Consolidated Balance Sheets.

Warrants

9 Months Ended

Jan. 31, 2023

(11) Warrants

Equity Classified Warrants

On April 8, 2019, the Company issued and sold 1,542,000 shares of common stock, and pre-funded warrants to purchase up to 3,385,680 shares of common stock. The public offering price for the pre-funded warrants was equal to the public offering price of the common stock, less the $0.01 per share exercise price of each warrant. The pre-funded warrants have no expiration date. As of January 31, 2023, all of the pre-funded warrants had been exercised.

The underwritten public offering also included the issuance of common stock warrants to purchase up to 4,927,680 shares of common stock that have an exercise price of $3.85 per share and expire five years from the issuance date. As of January 31, 2023, common warrants to purchase 732,500 shares of the common stock had been exercised.

The pre-funded and common warrants issued in the Company’s April 8, 2019 public offering did not meet the criteria to be classified as a liability award and therefore were treated as an equity award and recorded as a component of shareholders’ equity in the Consolidated Balance Sheets.